A PHASE III STUDY OF BMS-188667 IN SUBJECTS WITH ACTIVE RHEUMATOID ARTHRITIS
Phase 1
- Conditions
- -M069M069
- Registration Number
- PER-086-02
- Lead Sponsor
- BRISTOL MYERS SQUIBB PERU S.A.,
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Meet criteria of American Rheumatism Association for the diagnosis of rheumatoid arthritis and the American College of Rheumatology functional classes I, II III or IV
Participants must be taking 1 or more DMARDs and/or biologic approved for rheumatoid arthritis (RA) for at least 3 months and be on a stable dose for 28 days prior to Day 1.
Exclusion Criteria
Other auto-immune disease as a main diagnosis (e.g. Systemic Lupus Erythematosus [SLE], Scleroderma)
Active tuberculosis (TB) requiring treatment within last 3 years
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method